GPS tracking and monitoring technology.

To bring the tools developed for heritage to the management of healthcare data.

Next generation of high performance alloys.

Cancer diagnostics.

Advanced materials business which licences patents related to nanomaterials.

Optical neural networks.

Maritime trade and transport simulation.

To improve the ESG outcomes of publicly traded corporations by enhancing the efficacy of shareholder ownership rights.

A lean spin-out, social enterprise focusing on developing a fast rapid COVID-19 test. Joint Oxford University and OSCAR company.

The OxSight ‘SmartSpecs’ help sight impaired and blind people to navigate independently, avoid collisions and see in the dark.

OxSonics provide economic and scalable life-changing treatments to solid tumour cancer patients.

OxStem is a developer of cell programming therapies.

OxStem Beta will generate novel therapies to stimulate formation of new beta cells in the pancreas
(neogenesis) by targeting pathways that are normally only active during development or following
pancreatic injury.

OxStem Immuno aims to develop small molecule drugs that augment macrophage efferocytosis in
vitro and enhance tissue repair in vivo. These therapies will supercede the need for cell transplantation
or cytokine therapy in the context of tissue repair for chronic wounds and a range of inflammatory
conditions.

Developing 3D printing techniques to produce a range of tissue-like and functional tissues for medical research and clinical applications. Their vision is to ultimately produce tissues that can be used in the clinic for organ repair or replacement.

Tissue expander solutions for the primary use in reconstructive and dental surgery.

Oxvalue.ai offers a useful new approach for appraising technology, and an important guide for decision-making in technology investment, transfer and commercialisation.

The technology consists of two patent families which collectively enable the development of cost effective, off-the-shelf vaccines based on a proprietary dendritic cell subset for the treatment of solid tumour cancers. The technology overcomes certain key roadblocks previously associated with dendritic cell vaccine technology.

OxVent Limited is a joint-venture social enterprise that will license the OxVent ventilator design for international deployment in Covid19 and beyond, and provide consultancy on its testing, regulatory approval and manufacturing.

Biopharmaceutical company treating patients with chronic infectious diseases and cancer. In 2007 Oxxon Therapeutics was acquired by Oxford BioMedica plc.